Legend Motors Featured on Spike TV Hit Series Trucks!

Mon, 07 Jan 2008 22:25:05 GMT

Lawton, MI – Legend Motors Worldwide (Pink Sheets: LMWW) a subsidiary of LMWW Holdings specializing in classic tribute cars from the 60's and 70's for the automobile enthusiast, today filmed another segment of hit series Trucks!

In 2007, Legend Motors was featured in segment 14 of the hit Spike TV show Trucks. Those who wish to view the episode may do so by purchasing a copy via Apple iTunes.

"The last time we were featured, we received such an overwhelming response that kept our phones ringing. And more importantly, our customers were excited to see our company featured on the show. When approached by Spike TV to be featured on Trucks again in 2008, we jumped at the opportunity, commented Legends President Ian Marsh.

About Legend Motors Worldwide

Legend Motors Worldwide is focused on delivering a complete line of vintage cars from the 30's, 40's, 50's, 60's and 70's - a legendary period of automotive that spawned classic designs that everyone wanted as a kid. Legend Motors is a component car designer and assembler that handcrafts an in-house designed chassis with all other required items including wiring, plumbing, brakes, interior wheels, tires and paint completed at its own factory. Legend Motors delivers state-of-the-art versions of these cars that are otherwise unattainable for most car enthusiasts. Our dealer network is available to install the motor, dealer prep and deliver your car starting at $65,000.

This press release does not constitute an offer to sell or the solicitation of any offer to buy any securities of Legend Motors Worldwide, nor shall there be any sale of any such security in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Forward looking statements: This press release and other statements by Legend Motors may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for earnings and revenues, other future financial or business performance, strategies and expectations. Forward-looking statements are typically identified by words or phrases such as "believe", "expect", "estimate", "potential", or future/conditional verbs such as "will", "should", and "could".

The year 2007 contained significant milestones for Amarillo Biosciences, Inc. (OTC BB: AMAR.OB - News).

Mon, 03 Dec 2007 22:45:15 GMT

AMAR is nearing completion of Phase 2 enrollment of 90 patients in Turkey for Behcet’s disease (BD). Phase 2 enrollment of 80 patients in the US for oral warts (human papillomavirus) in HIV+ patients is nearing 50% completion. Clinical data using the universally accepted mouse model was generated in 3 separate laboratories which showed that low-dose oral interferon protected mice against fatal influenza. The planning for a Phase 2 COPD cough study in the US was completed and a patent was filed on the use of low-dose oral interferon to treat chronic cough.

Amarillo Biosciences, Inc. is a public company working to bring low-dose oral interferon to your pharmacy. AMAR is the world leader in low-dose oral interferon technology with 13 issued plus 2 pending patents.

What is interferon and when did the FDA approve it for treatment of human diseases?

Fifty years ago scientists discovered an antiviral protein, subsequently, named interferon because it “interfered” with the growth of flu virus. Twenty years ago, the FDA granted the first approval for injectable interferon to treat hairy cell leukemia. Since then, injectable interferon has gained FDA approval to treat various cancers, and viral and autoimmune diseases.

What is the market size for oral interferon?
The market is not yet developed for oral interferon. AMAR believes the potential market in the USA and EU for oral interferon treatment of chronic cough, influenza and oral warts exceeds $2 billion. The annual world market for human use of injectable interferon in 2005 was greater than $5 billion (Med Ad News, June 2006).

Why is injectable interferon so toxic?
Interferon is a powerful immunomodulating protein with action on major organ systems. It was assumed that for interferon to be effective, it must reach a high blood level achieved only after interferon was injected in doses above a million International Units (IU) to counteract the kidney’s efficient clearance of interferon from the blood. Large doses of injectable interferon typically cause moderate to severe side effects.

Amarillo’s technology is low-dose, oral administration of interferon, not high-dose injectable interferon. We can achieve the benefits of interferon therapy without the toxicity of injectable interferon by placing tiny amounts of interferon in contact with the oral-pharyngeal mucosa (the lining of the mouth and throat). The interferon activates systemic beneficial effects, not just a topical effect. Interferon is naturally produced in the nasal secretions in tiny amounts and trickles down the throat to activate an immune response. If a virus, rickettsia, chlamydia or mycoplasma is inhaled, the tissue of the nose responds by producing tiny amounts of interferon in the nasal secretions which sends a message to the immune system, “Hey, what you just inhaled is worthy of an immune response; it wasn’t dust or pollen. What was inhaled induced interferon, so a systemic immune response is needed.” AMAR first tested oral interferon in dogs with parvovirus, cats with feline leukemia and cattle with shipping fever (bovine respiratory disease). Then AMAR followed up with clinical studies in swine, horses, poultry, rats, mice and now humans. AMAR is conducting human clinical trials in two diseases, known as “Orphan Diseases” since they affect fewer than 200,000 patients.

Big Pharma companies generally will not work on small market diseases so the government offers incentives to companies to work on Orphan Diseases. AMAR has been granted Orphan Disease Designation by FDA for oral warts in HIV+ patients and for Behçet’s disease which means that we will enjoy 7 year’s exclusivity in the market place, once we achieve FDA approval. Oral warts are caused by papillomavirus and can be a functional as well as a cosmetic problem for patients who are HIV positive. AMAR is currently enrolling patients in a Phase 2 study at twelve clinical sites in San Francisco, Baltimore, Chicago, New York City, Boston, Philadelphia, Newark, Dallas, Augusta (GA), Ft. Lauderdale, San Antonio and Lexington (KY). As of today, 32 oral warts patients have been enrolled at 10 active clinical sites and 3 patients are in the screening process so we expect enrollment to soon reach 35 subjects. An additional two investigators are in the process of obtaining Institutional Review Board (IRB) approval. A thirteenth investigator just agreed to join the study.

AMAR will focus more resources and attention to these major clinical indications. Clinical data from humans treated for idiopathic pulmonary fibrosis (IPF) is excellent, but the number of patients is small. AMAR is generating Phase 2 human study of COPD patients to answer the question: “Can low-dose oral interferon treat chronic cough?” The clinical data on influenza are even more compelling than clinical data on IPF because large scale human flu studies have been conducted. Moreover, animal data from multiple laboratories indicate that oral or intranasal interferon is life-saving against influenza.

After the ongoing Phase 2 COPD study is completed in 2008, it is planned that AMAR will conduct a COPD Phase 3 study in 2009. AMAR has FDA Orphan Drug Designation for oral interferon treatment of oral warts in HIV+ patients; although, the market for oral warts in HIV+ patients is small, compared to chronic cough or influenza.

MILESTONES

The Milestones anticipated in the next year are as follows:

Q4 -2007
Completion of enrollment of 90 Behcet’s disease (BD) (Phase 2) patients in Turkey

Flu data announced from animal studies in Germany

Q1&2 - 2008
Start of enrollment in COPD cough study Animal health license granted

Completion of enrollment for oral warts and COPD cough studies

Announcement of completion of BD study and results

Completion and announcement of results of cough study

Start enrollment in flu studies in Australia and Asia

Start of hepatitis C study in Taiwan

ABI seeks Orphan Drug Designation for oral warts in EU

Q3&4 - 2008
Completion and announcement of results of oral warts Phase 2 study

Completion and results of Phase 2 flu study in Australia

Human health license for one or more clinical indications in the USA and Europe

News In Review:

October 9th 2007
Amarillo Biosciences Issues Clinical Trials Update

August 2nd 2007
Amarillo Biosciences Plans a Human Influenza Clinical Trial in Perth, Australia

June 21at 2007
Amarillo Biosciences Announces Two Additional Clinical Sites for Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

May 31st 2007
CytoPharm to Conduct Hepatitis C Trial and Seek Regulatory Approval for Amarillo Biosciences' Low Dose Oral Interferon

May 2nd 2007
Amarillo Biosciences Issues Corporate Update on Influenza and Hepatitis C Research and Behcet's Disease and Oral Warts Phase 2 Trials

February 12th 2007
Amarillo Biosciences Announces the Publication of Influenza Data

February 8th 2007
Amarillo Biosciences Announces Open Enrollment in Its Phase 2 Study of Orally Administered Interferon Alpha in the Treatment of Oral Warts in HIV-Positive Patients

First Financial News

Legend Motors Featured on Spike TV Hit Series Trucks!

The year 2007 contained significant milestones for Amarillo Biosciences, Inc. (OTC BB: AMAR.OB - News).